Novel peptide dimers as agonists of the erythropoietin (epo) receptor, and associated methods of synthesis and use
CA 2370322 A1 · Owner: Balu, Palani · Inventors: Balu, Palani
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel peptide dimers are provided that bind and activate the erythropoietin receptor (EPO-R) or otherwise act as an EPO agonist. The novel compounds have a first peptide chain R1 and a second peptide chain R2 wherein R1 and R2 may , be the same or different and are linked through a linking moiety. R1 is approximately 10 to 40 amino acid residues in length and comprises the sequence X3X4X5GPX6TX7X8X9 (SEQ ID NO: 1) wherein X3 is C or Hoc X4 is R, H, L or W, X5 is M, F, I or nor-leucine (J) X6 is any one of the 20 genetically , coded L-amino acids or J X7 is W, 1-naphthylalanine (B) or 2-naphthylalanine (U), X8 is D, E, I, L or V, and X9 is C or Hoc. Similarly R2 comprises the , sequence …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 24, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 24, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 24, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.